MarketInOut Stock Screener Log In | Sign Up
 

Gossamer Bio Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 08/21/2026
Gossamer Bio Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization76.55 mln
Float298 mln
Earnings Date11/05/2026

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

-1.99
Caution advised

1-Year Forecast

1.66
Transformational upside

Relative Strength

8 / 100
Severely lagging

Debt / Equity

-0.43
Negative equity

Dividend Yield

0.00%
No dividend

Business Description

Gossamer Bio is a San Diego-based medical company working to bring a new treatment called seralutinib to patients suffering from pulmonary arterial hypertension, a serious condition affecting the lungs and heart. Their lead drug, taken through inhalation, works by targeting specific proteins in the body that drive the disease and is currently being tested in a large Phase 3 clinical trial. The company holds a licensing agreement that gives them the rights to develop and sell this drug and related compounds. Founded in 2015, Gossamer Bio is focused entirely on turning this promising therapy into an approved treatment option for patients in need.

Key Fundamentals

EPS-0.66
RPS0.22
ROIC-302
ROA-75.64
EBITDA, mln-113
EV / EBITDA-0.52
EV / EBIT-0.51
Revenue, mln53.29
EV / Revenue1.10

Financial Strength

Altman Z-Score-31.72
Piotroski F-Score 2 / 9
Beneish M-Score-1.99
1-Year Target Price1.66
Short Ratio2.22
Short % of Float19.71

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.32% 70 / 100   
1 Month 8.56% 78 / 100   
2 Months -53.12% 6 / 100   
6 Months -92.74% 1 / 100   
1 Year -92.07% 4 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us